Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMDC-GIR for Tongue Dysphagia
NCT02838316Phase 1Active, not recruiting
- Start
- May 2017
- Primary completion
- Dec 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of AMDC-USR in oropharyngeal dysphagia (2 arms). Primary endpoints: Study product-related Serious Adverse Events at 24 months and Study product-related, biopsy procedure-related, and injection procedure-related adverse events at 24 months. Started May 2017; status: active, not recruiting.
02
Drugs
AMDC-USR
03
Conditions
oropharyngeal dysphagia
Beyond the preview
Go deeper on NCT02838316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02838316.